Compare BUI & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BUI | REPL |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 601.7M | 692.8M |
| IPO Year | 2011 | 2018 |
| Metric | BUI | REPL |
|---|---|---|
| Price | $30.50 | $7.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.13 |
| AVG Volume (30 Days) | 64.1K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.27 | $2.68 |
| 52 Week High | $30.43 | $13.24 |
| Indicator | BUI | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 88.07 | 45.88 |
| Support Level | $25.57 | $6.90 |
| Resistance Level | N/A | $8.07 |
| Average True Range (ATR) | 0.39 | 0.55 |
| MACD | 0.11 | 0.04 |
| Stochastic Oscillator | 97.32 | 28.44 |
BlackRock Utility Infrastructure & Power Opportunities Trust is a closed-end management investment company. Its investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities issued by companies that are engaged in the Utilities, Infrastructure and Power Opportunities business segments anywhere in the world and by employing of writing (selling) call and put options.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.